#JPM24: Greg Verdine’s LifeMine eyes the clinic next year with T-cell immunosuppressive and antifungal

SAN FRANCISCO — LifeMine Therapeutics, a biotech informed by the long history of fungi, expects to enter the clinic early next year with a T-cell immunosuppressive and with an antifungal about six months later, CEO Greg Verdine told Endpoints News.

“I’m saying it for the first time…
Click here to view original post